Blastoid-HGBL cases also more frequently have MYC rearrangement, a complex karyotype, and TP53 aberrancies, whereas myeloid marker expression and KRAS and NRAS mutations occur exclusively in a subset of B-ALL cases. This evidence concerns the gene KRAS and acute lymphoblastic leukemia.